Investment Rating - The report maintains a "Buy" rating for the company [1] Core Insights - The company has successfully completed all primary and secondary endpoints in the Phase III clinical trial for ASC40, a treatment for moderate to severe acne, demonstrating excellent efficacy [7] - ASC40's treatment success rate was 33.2% compared to 14.6% in the placebo group, with a significant reduction in total lesions and inflammatory lesions [7] - The company is expected to submit for regulatory approval in 2025, with projected revenues starting in 2026 [7] Financial Projections - Total revenue is projected to be 1.28 million in 2024, with a significant increase to 40 million in 2026 and 100 million in 2027 [1] - The net profit attributable to the parent company is expected to decline to (300.94) million in 2024 and further to (454.44) million in 2025, before slightly improving to (445.21) million in 2027 [1] - The earnings per share (EPS) is forecasted to be (0.31) in 2024, (0.47) in 2025, and (0.46) in 2027 [1] Market Data - The closing price of the stock is 8.07 HKD, with a market capitalization of approximately 7,169.28 million HKD [5] - The company has a price-to-book ratio of 3.81 and a price-to-earnings ratio of (54.06) [5][1]
歌礼制药-B：ASC40痤疮适应症III期临床达到所有终点，疗效数据优秀-20250605